Opportunities
Search

Buyer: DAK-Gesundheit | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2026-10-05

Buyer: DAK-Gesundheit | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2026-10-05

Buyer: AOK Nordost - Die Gesundheitskasse | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2026-10-05

Buyer: Gemeente Rotterdam | Notice type: cn-standard | Procedure: open | Contract: services | Deadline: 2026-10-05

Buyer: Gemeente Rotterdam | Notice type: cn-standard | Procedure: open | Contract: services | Deadline: 2026-10-05

Summary: The fiscal year 2026 (FY26) Peer Reviewed Cancer Research Program (PRCRP) Impact Award supports mature research that will have a near-term impact on clinical cancer care in one of the congressionally directed FY26 PRCRP Topic Areas. Applicants must consider how the research project will lead to the advancement of knowledge in cancer research, patient care and/or treatment options in the Military Health System (MHS).Distinctive Features:• Applications must include preliminary data to support feasibility of the study.• Projects must have strong potential to result in a near-term impact in cancer.• The funding mechanism allows clinical trials.• This funding mechanism allows for a single Principal Investigator (PI), or two partnering PIs referred to as the Initiating PI and the Partnering PI. Only the Initiating PI will submit a pre-application, but both PIs will need to submit full applications. The Partnering PI’s application is an abbreviated package specific to their distinct portion of the research project. Be advised, both applications for a research project may be withdrawn if the initiating or partnering application is rejected or administratively withdrawn.

Summary: The fiscal year 2026 (FY26) Peer Reviewed Cancer Research Program (PRCRP) Idea Award (IA) supports innovative, untested, high-risk/potentially high-reward concepts, theories, paradigms, and/or basic cancer research. The advancement of knowledge in cancer research, patient care, and/or treatment options in the Military Health System (MHS) is critical to Service Members, Veterans, other military beneficiaries and the American public.Distinctive Features: The proposed project should demonstrate creative thinking and innovation.• Incremental advances, the next logical step, or switching a model system from one cancer to another cancer are not appropriate for this award.• Inclusion of preliminary data is not required; however, the project must be based on strong scientific rationale.• New for FY26: Early Career Investigator Option: The Early Career Investigator option is designed to support the continued development of promising independent investigators that are early in their faculty appointments.

Summary: The fiscal year 2026 (FY26) Peer Reviewed Cancer Research Program (PRCRP) Clinical Trial Award (CTA) supports the rapid implementation of clinical trials with the potential to have a significant impact on the treatment or management of cancer within at least one of the FY26 PRCRP Topic Areas. Clinical trials proposed may evaluate promising new products, pharmacologic agents (drugs or biologics), devices, clinical guidance, and/or emerging approaches and technologies. Proposed projects may range from small proof-of-concept trials (e.g., pilot, first-in-human, phase 0) that evaluate the effects of interventions or inform the design of more advanced trials to large-scale trials (up to phase III) to determine efficacy in relevant patient populations.Distinctive Features:• Applications to this award mechanism must include a clinical trial.• Projects can range from phase 0 to phase III.• If an Investigational New Drug (IND) application, Investigational Device Exemption (IDE), or equivalent, is required, a regulatory application must be submitted to the relevant regulatory agency by the Clinical Trial Award application submission deadline. The regulatory application should be specific to the product and indication to be tested in the proposed clinical trial.• Applications are required to include patient advocates.• Animal studies are NOT allowed under this award mechanism. All preclinical work must be completed prior to the award start date.

Buyer: Instituto de Turismo de España (TURESPAÑA) | Notice type: cn-standard | Procedure: open | Contract: works | Deadline: 2026-10-06

Buyer: Hoogheemraadschap Hollands Noorderkwartier | Notice type: pin-rtl | Procedure: open | Contract: works | Deadline: 2026-10-06

Buyer: VAUBAN 21 | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2026-10-06

This notice of funding opportunity (NOFO) invites applications designed to examine the efficacy and clinical effectiveness of multimodality digital health technology approaches to the remote management of diabetes.

Expected Outcome:This call for proposals supports implementation of the following key principles of the European Pillar of Social Rights: (3) equal opportunities; (5) secure and adaptable employment; (6) wages; (7)information about employment conditions and protection in case of dismissals; (8) social dialogue and involvement of workers; (10) healthy, safe and well –adapted work environment and data protection. The general objective of this call for proposals is therefore contributing to the implementation of the key principles of the pillar in the area of posting of workers. The specific objectives are the following:a) To promote transnational cooperation among public authorities and stakeholders, including the promotion of the use of IMI and sharing experiences and best practices in this respect;b) To increase the accessibility, transparency and quality of the information concerning th...

HBCU-UP provides awardsto strengthen STEM undergraduate education and research at Historically Black Colleges and Universities (HBCUs).Support is available through thefollowing tracks: Targeted Infusion Projects (TIP), which provide support to achieve a short-term, well-defined goal for enhancing and innovating undergraduate STEM education at an HBCU. Research on Broadening Participation in STEMprojects (BPR), which provide support for researchthat seeks to create and study new theory-driven models and innovations related to the participation and success of underrepresented groups in STEM undergraduate education, especially African Americans. Research Initiation Awards (RIA), which provide support for STEM faculty with no prior or recent research funding to pursue research at the home institution, another research-intensive institution, an NSF-funded research center, or a national laboratory. Implementation Projects (IMP), which provide support to design, implement, study, and assess comprehensive institutional efforts for increasing the number of students receiving undergraduate degrees in STEM and enhancing their preparation by strengthening STEM education and research. Broadening Participation Research Centers (BPRC),which provide support to create centers that conduct research on STEM education and broadening participation and build the intellectual infrastructure to facilitate the creation, integration, and transfer of new knowledge. Other Funding Opportunities include EArly-Concept Grants for Exploratory Research (EAGER), Rapid Response Research (RAPID), conference, a...

Buyer: Stichting Lucas Onderwijs | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2026-10-07

Buyer: Stichting Openbaar Primair Onderwijs Utrecht | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2026-10-07

Summary: The fiscal year 2026 (FY26) Pancreatic Cancer Research Program (PCARP) Focused Pilot Award supports the exploration and development of impactful and innovative concepts under a patient-centered focus area of pancreatic cancer research that could ultimately lead to major advancements that will have a profound effect on patients’ overall quality of life. The research this award supports should strive to produce robust preliminary data that can serve as a foundation for future clinical or real-world research application. Distinctive Features: This award mechanism allows, but does not require, preliminary data. Applications can support clinical research studies; however, this mechanism does not allow clinical trials. Preclinical animal studies do not meet the intent of this mechanism.

Summary: The fiscal year 2026 (FY26) Pancreatic Cancer Research Program (PCARP) Translational Research Partnership Award supports partnerships between clinicians, population scientists, applied scientists and/or basic scientists that will accelerate the movement of promising ideas in pancreatic cancer toward clinical applications. The partnership must include at least one member with expertise in pancreatic cancer research or pancreatic cancer patient care. All applications must address at least one of the FY26 PCARP Focus Areas. ·        This award mechanism requires preliminary data to support feasibility of the research hypothesis(es) and research approaches. However, these data do not necessarily need to originate from studies of pancreatic cancer. Applications can support retrospective tissue analysis, correlative studies and pilot clinical trials; however, this mechanism does not allow large-scale clinical trials. ·        The Translational Research Partnership Award requires two Principal Investigators (PIs) referred to as the Initiating PI and the Partnering PI. Only the Initiating PI will submit a pre-application, but both PIs will need to submit at the full application stage. The partnering PI’s application is an abbreviated package specific to their distinct portion of the research project. Be advised, all associated applications for a research project may be withdrawn if the initiating or partnering application is rejected or administratively withdrawn.

Summary: The fiscal year 2026 (FY26) Pancreatic Cancer Research Program (PCARP) Idea Development Award supports the development of innovative, high-risk/high-reward research that could lead to critical discoveries or major advancements that will accelerate progress in improving outcomes for individuals with pancreatic cancer. This award mechanism supports innovative ideas with the potential to yield impactful data and new avenues of investigation. All applications must address at least one of the FY26 PCARP Focus Areas. Distinctive Features: This award mechanism requires preliminary data relevant to the proposed project. Applications can support clinical research studies; however, this mechanism does not allow clinical trials. Partnering Principal Investigator (PI) Option for Early-Career Investigator: This funding mechanism offers a higher level of funding for applications that propose to partner an experienced PI (i.e., Initiating PI, who will serve as the mentor) with an Early-Career Investigator (i.e., Partnering PI) wishing to pursue a career in pancreatic cancer research. For this option, only the Initiating PI will submit a pre-application, but both PIs will need to submit at the full application stage. The partnering PI’s application is an abbreviated package specific to their distinct portion of the research project. Be advised, all associated applications for a research project may be withdrawn if the initiating or partnering application is rejected or administratively withdrawn.

Buyer: Alliander N.V. | Notice type: cn-standard | Procedure: open | Contract: works | Deadline: 2026-10-08

Buyer: Infraestruturas de Portugal, SA | Notice type: cn-standard | Procedure: open | Contract: works | Deadline: 2026-10-08

Buyer: GCS Achats Santé en Occitanie | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2026-10-08

Buyer: SEROC | Notice type: cn-standard | Procedure: open | Contract: services | Deadline: 2026-10-08

Expected Outcome:Project results are expected to contribute to all of the following expected outcomes:Methods and tools to support measurement, simulation and validation of non-exhaust pollutant emissions in road and railway transport into the environment;Estimates on the impact of these pollutants on human health, terrestrial ecosystems and the aquatic environment (including biodiversity in these ecosystems) with particular focus on microplastics and other heavier non-airborne particles;Delivery of better emission factors for emission inventories and projections, including the European Monitoring and Evaluation Programme (EMEP), also for resuspension, for which little knowledge exists today;Recommendations and mitigation strategies including the determination of appropriate KPIs and assessing the effectiveness of control measures with an appropriate cost-benefit analysis to understand t...

Expected Outcome:Project results are expected to contribute to some of the following expected outcomes:Improved quality and reduced uncertainty of global and regional climate change projections;Critical knowledge and data gaps in Earth system science as identified in the IPCC Sixth Assessment Report (AR6) and other authoritative sources, are addressed, ensuring that future climate assessments are grounded in the most comprehensive and up-to-date scientific evidence;New climate science evidence is generated that is relevant for policy needs and for informing climate action. Scope:The global community’s ability to mitigate and adapt to climate change requires the continuous advancement of climate science and related disciplines. International climate policy is informed primarily by the assessments made by the Intergovernmental Panel on Climate Change (IPCC), which provides the most compreh...